You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(07.06)︱中國心連心化肥中期淨利潤預增不低於200%;中國聖牧獲中國蒙牛增持12.48%股份

【業績預吿】

中國心連心化肥(01866.HK)預計中期淨利潤同比增長不低於200%

雅迪控股(01585.HK)中期純利預增不少於40%

艾德韋宣集團(09919.HK):預計中期純利約3800萬元

精熙國際(02788.HK)預期中期綜合溢利同比增加

【運營數據】

吉利汽車(00175.HK):6月總銷量10.02萬部 領克品牌銷量按年增長29%

時代中國控股(01233.HK):上半年合同銷售453.79億元 同比增長39.34%

合生創展集團(00754.HK)上半年總合約銷售額212.27億元 同比上升63.1%

上坤地產(06900.HK)上半年累計合約銷售額達167.2億元

中廣核電力(01816.HK):上半年核電機組總髮電量升5.12%至1011.27億千瓦時

秦港股份(03369.HK)上半年吞吐量增6.70%至1.87億噸

信利國際(00732.HK):上半年綜合營業淨額110.31億港元 同比增加6.8%

捷利交易寶(08017.HK):6月註冊用户數量61.45萬户 同比增長81.1%

【增減持】

睿見教育(06068.HK)獲控股股東劉學斌增持255.4萬股

華泰證券(06886.HK)大股東國信集團增持236.36萬股H股

【併購出售】

華昱高速(01823.HK)擬1363萬元出售華昱健康酒業(深圳)10%股權

【要約私有化】

展程控股(01854.HK):佳源1.16億港元拿下公司控股權 溢價7.14%提全購 明日復牌

【投資運營】

和黃醫藥(00013.HK)在中國啟動新型ERK抑制劑HMPL-295治療晚期實體瘤I期臨牀試驗

和鉑醫藥-B(02142.HK):巴託利單抗治療全身型重症肌無力的II期概念驗證性試驗的積極研究結果

中國聖牧(01432.HK):中國蒙牛增持12.48%股份 持股增至29.99%

贛鋒鋰業(01772.HK):Mariana鋰鹽湖項目年化設計產能2萬噸氯化鋰工廠建設獲批

華潤醫藥(03320.HK)擬收購博雅生物(300294.SZ)控股權獲國資委批覆

石四藥集團(02005.HK)與中國藥科大學成立校企聯合實驗室 於新藥研發等領域展開合作

金馬能源(06885.HK):聯交所就公司股份全流通授出上市批准

CHESHI(01490.HK)擬採用中文名稱“車市科技有限公司”

【回購註銷】

復星國際(00656.HK)7月6日耗資1114.56萬港元回購100萬股

海爾智家(06690.HK)7月6日耗資507萬元回購20.26萬股A股

富智康集團(02038.HK)7月6日耗資544.75萬港元回購430萬股

復旦張江(01349.HK)7月6日耗資200.9萬港元回購40萬股

時代中國控股(01233.HK)7月6日耗資197.65萬港元回購22.2萬股

惠理集團(00806.HK)7月6日耗資99.8萬港元回購20.8萬股

【股權激勵】

比高集團(08220.HK)授出2562萬份購股權

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account